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Summary
Background Women with twin pregnancy are at high risk for spontaneous preterm delivery. Progesterone seems to be 
eﬀ ective in reducing preterm birth in selected high-risk singleton pregnancies, albeit with no signiﬁ cant reduction in 
perinatal mortality and little evidence of neonatal beneﬁ t. We investigated the use of progesterone for prevention of 
preterm birth in twin pregnancy. 
Methods In this double-blind, placebo-controlled trial, 500 women with twin pregnancy were recruited from nine UK 
National Health Service clinics specialising in the management of twin pregnancy. Women were randomised, by 
permuted blocks of randomly mixed sizes, either to daily vaginal progesterone gel 90 mg (n=250) or to placebo gel 
(n=250) for 10 weeks from 24 weeks’ gestation. All study personnel and participants were masked to treatment 
assignment for the duration of the study. The primary outcome was delivery or intrauterine death before 34 weeks’ 
gestation. Analysis was by intention to treat. Additionally we undertook a meta-analysis of published and unpublished 
data to establish the eﬃ  cacy of progesterone in prevention of early (<34 weeks’ gestation) preterm birth or intrauterine 
death in women with twin pregnancy. This study is registered, number ISRCTN35782581.
Findings Three participants in each group were lost to follow-up, leaving 247 analysed per group. The combined 
proportion of intrauterine death or delivery before 34 weeks of pregnancy was 24·7% (61/247) in the progesterone 
group and 19·4% (48/247) in the placebo group (odds ratio [OR] 1·36, 95% CI 0·89–2·09; p=0·16). The rate of 
adverse events did not diﬀ er between the two groups. The meta-analysis conﬁ rmed that progesterone does not prevent 
early preterm birth in women with twin pregnancy (pooled OR 1·16, 95% CI 0·89–1·51).
Interpretation Progesterone, administered vaginally, does not prevent preterm birth in women with twin pregnancy. 
Funding Chief Scientist Oﬃ  ce of the Scottish Government Health Directorate.
Introduction 
Multiple pregnancies accounted for 1·6% of all births in 
the UK during 2007,1,2 with more than 98% of these 
multiple births being twin births.2 Rates of stillbirth and 
neonatal mortality for multiple pregnancies are 14·9 and 
19·8 per 1000 livebirths, respectively, and are three to 
eight times higher than for singleton pregnancies.3 The 
economic costs of health-care provision in the ﬁ rst 5 years 
of life are twice as high per child after twin birth compared 
with singleton birth.4 
Prematurity continues to be the major cause of neonatal 
death in multiple births, with preterm labour potentially 
the most treatable cause of prematurity.3 In the long term, 
the morbidity in both singleton and multiple survivors of 
preterm birth is well documented, and is known to lead to 
poor health and reduced achievement both in school and 
in adulthood.5 Such morbidity is associated with major 
ﬁ nancial costs to the health service, and with personal 
suﬀ ering to the individuals and their families.
No eﬀ ective interventions have been shown to prevent 
preterm delivery in twin pregnancy. By contrast, three 
large randomised trials6–8 have suggested that progesterone 
might prevent preterm delivery in high-risk singleton 
pregnancy. The likelihood of preterm birth in women 
with singleton pregnancy who are identiﬁ ed at risk of 
preterm delivery because of either a previous preterm 
delivery6,7 or a short cervix8 might be reduced by antenatal 
progesterone. Importantly, evidence that a reduction in 
the rate of preterm birth is accompanied by neonatal 
beneﬁ t is scarce because there is no reduction in perinatal 
mortality, and risk of neonatal sepsis is the only secondary 
neonatal outcome that is reduced in babies of women 
with singleton pregnancy treated with antenatal 
progesterone.9
The STOPPIT study (STudy Of Progesterone for the 
Prevention of Preterm Birth In Twins) was designed to 
test the hypothesis that the occurrence of delivery or 
intrauterine death before 34 weeks and 0 days of gestation 
would be lower in women with twin pregnancy randomly 
assigned to progesterone gel than in those randomly 
assigned to matching placebo.
Methods
Participants
Women were recruited between Dec 1, 2004, and April 30, 
2008 from specialised antenatal clinics caring for women 
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with multiple pregnancy at nine UK National Health 
Service hospitals. All women with a twin pregnancy, with 
gestation and chorionicity established by scan before 
20 weeks’ gestation, and attending the antenatal clinic 
during the recruitment period were eligible for 
recruitment. Women were not eligible if their pregnancy 
was complicated by a recognised structural or 
chromosomal fetal abnormality at the time of 
recruitment, or if they had contraindications to 
progesterone, planned cervical suture, planned elective 
delivery before 34 weeks’ gestation, or planned 
intervention for twin-to-twin transfusion before 22 weeks’ 
gestation. Women with higher multiple pregnancy were 
also excluded.
Participants gave written informed consent, and the 
study was granted approval by the West Glasgow Ethics 
Committee 1 (reference 04/S0703/13).
Procedures
We aimed to recruit and randomly assign women at 
22 weeks’ gestation. When possible, the project was 
discussed with women at booking, and again at 
22 weeks’ gestation. All women had at least 1 week to 
decide whether to participate. Participants were 
randomly assigned to either daily progesterone gel 
(90 mg; Crinone [Serono, Feltham, Middlesex, UK]) or 
to placebo gel administered vaginally by the participant 
and starting at 24 weeks and 0 days of gestation. Drugs 
were supplied in a sealed opaque covering. Every cover 
contained a single-use, one piece, white polyethylene 
applicator with a twist-oﬀ  top, designed for intravaginal 
self-insertion. Each applicator contained 1·45 g of gel 
and delivered 1·125 g of gel, containing either 8% 
progesterone or excipients (glycerin, light liquid 
paraﬃ  n, hydrogenated palm oil glyceride, carbopol 
974P, sorbic acid, polycarbophil, sodium hydroxide, and 
puriﬁ ed water). 
We used a randomisation schedule with permuted 
blocks of randomly mixed sizes to make up treatment 
packs (either active or placebo) for every patient, which 
were held in individual hospital pharmacies until use. 
On recruitment, the local researcher (usually a midwife) 
telephoned the interactive voice response randomisation 
application at the UK Clinical Research Network 
registered trials unit (The Centre for Healthcare 
Randomised Trials [CHaRT], in the Health Services 
Research Unit, University of Aberdeen, UK), to be 
given a participant number that corresponded to a 
speciﬁ c treatment pack. We used a minimisation 
algorithm incorporating hospital and chorionicity to 
assign participants to the randomised treatment 
group. 
All study personnel and participants were masked to 
treatment assignment for the duration of the study. Only 
the study statistician and the independent Data 
Monitoring Committee had access to unblinded data, 
but none had any contact with study participants.
Outcomes
The primary outcome was delivery or intrauterine death 
before 34 weeks and 0 days of gestation. We used 
delivery of the ﬁ rst twin to deﬁ ne the time of delivery. If 
one twin died in utero before 34 weeks and the other 
was born alive after 34 weeks, intrauterine fetal death 
was deﬁ ned as occurring before 34 weeks. The 
gestational age was calculated from ultrasound scan 
done before 20 weeks. The maternal secondary outcomes 
were gestation at delivery, method of delivery 
(spontaneous vaginal delivery, vaginal breech, forceps 
or ventouse, or caesarean section), duration of each 
stage of labour, and safety outcomes such as duration of 
stay in hospital. Neonatal secondary outcomes were 
neonatal unit admission and duration of neonatal unit 
care. We also ascertained maternal satisfaction by 
questionnaire. Women were followed up from 
randomisation until they gave birth. Outcomes were 
recorded from the hospital notes, and entered into a 
web-based data capture system by a trained clinician, 
usually a study midwife. 
Statistical analysis 
The proportion of deliveries before 34 weeks’ gestation 
in twin pregnancy is about 20% (Chalmers J, Information 
Services Division, NHS Scotland, Edinburgh, UK, 
personal communication). Our study size of 250 women 
per group gave 85% power at 5% signiﬁ cance level to 
show a reduction in the rate of preterm delivery or 
intrauterine death before 34 weeks’ gestation from 20% 
to 10% in the active treatment group and was based on a 
conservative estimate of likely eﬀ ect size derived from 
previous studies.6,7 
347 analysed
     3 excluded from analysis (no outcome 
         data available)
3 lost to follow-up (because of withdrawal 
    of consent or not traceable after moving 
    out of study area)
983 excluded
         234 did not meet eligibility criteria
         749 declined to participate 
250 allocated to placebo and 
         received allocated intervention
500 enrolled and randomised
1483 assessed for eligibility
347 analysed
     3 excluded from analysis (no outcome 
        data available)
3 lost to follow-up (because of  withdrawal 
    of consent or not traceable after moving 
    out of study area) 
250 allocated to progesterone and 
        received allocated intervention
Figure 1: Trial proﬁ le
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Analysis was done by intention to treat and followed a 
prespeciﬁ ed statistical analysis plan. For the primary 
outcome, the odds ratio (OR) of the treatment eﬀ ect, 
adjusting for the minimisation covariate (chorionicity), 
was estimated with a 95% CI, and associated likelihood 
ratio p value with logistic regression. We also undertook 
a predeﬁ ned subgroup analysis of the primary outcome 
by monochorionicity (yes or no). We analysed continuous 
maternal secondary outcomes with normal linear 
regression models, adjusting for chorionicity. Treatment 
eﬀ ects, 95% CIs, and p values were calculated as described 
in the statistical analysis plan. We analysed binary 
categorical secondary outcomes with logistic regression 
as per the primary outcome. For data with multiple 
categories (eg, method of delivery), we compared the two 
randomised groups with a proportional odds model. 
Fetal outcomes allowed for the clustering within twins. 
Analyses were as for the maternal outcomes, except with 
the addition of mother as a random eﬀ ect in the linear 
and logistic regression models. No missing data were 
imputed. No adjustment was made for any multiple 
comparisons. An independent Data Monitoring 
Committee met regularly throughout the study. No 
formal interim analyses were under taken, and so no 
adjustment was made. All statistic al analyses were 
undertaken in SPSS for Windows (version 17.0.0) and 
Stata (version 10.1). 
The trial was registered on EUDRAct, number 2004-
000780-10, and as an International Standard Randomised 
Controlled Trial, number ISRCTN35782581.
Meta-analysis 
We did an electronic search of the published medical 
literature (PubMed and Cochrane Controlled Trials 
Register) for studies in which women with twin 
pregnancy were randomly allocated to treatment with a 
progestogen (including progesterone, 17-hydroxy-
progesterone caproate) or placebo in the second or third 
trimester with the intention to prevent preterm birth. 
We used the search terms “preterm birth” AND 
[“progesterone” OR “17 hydroxyprogesterone caproate” 
OR “progestogen”] AND [“pregnancy multiple” OR 
“pregnancy twin”] AND “randomised controlled trial” 
AND “human”. We considered all published randomised 
controlled trials in which progestogens were given to 
women with twin pregnancy for the prevention of 
preterm birth. We excluded those in which progestogens 
were given to women with symptoms of preterm labour, 
or in which data were available in abstract form only. 
Two reviewers (J E Norman and J Norrie) reviewed 
identiﬁ ed papers for relevance and quality, and 
abstracted the data. Published studies were assessed for 
quality according to Jadad’s quality assessment scale.10
Our prespeciﬁ ed primary outcomes were the incidence 
of delivery or intrauterine fetal death before 34 weeks’ 
gestation. When data for our primary outcome of interest 
were not available in the published report, we contacted 
the relevant chief investigator to obtain the required 
information. We calculated ORs and 95% CIs for the 
primary outcome. 
Role of the funding source 
Neither the funder nor the supplier of active and placebo 
drugs had any role in study design, data collection, data 
Progesterone Placebo Odds ratio 
progesterone vs 
placebo (95% CI)
p value
n Event (%) n Event (%)
All pregnancies 247 61 (24·7%) 247 48 (19·4%) 1·36 (0·89–2·09) 0·16*
Monochorionic pregnancies 46 10 (21·7%) 45 14 (31·1%) 0·62 (0·24–1·58) ..
Dichorionic pregnancies 201 51 (25·4%) 202 34 (16·8%) 1·73 (1·06–2·83) ..
*Refers to p value for proportion in progesterone versus placebo group (from a logistic regression model adjusting for 
chorionicity). For test of interaction between monochorionic and dichorionic pregnancies, p=0·056.
Table 2: Primary outcome (proportion of women delivering or with intrauterine death before 34 weeks) 
overall and by subgroup of chorionicity
Progesterone 
(n=250)
Placebo 
(n=250)
Demographics and lifestyle
Mean age (years [SD; min–max]) 33 (5; 18–44) 33 (6; 19–50)
Current smoking 44 (18%) 31 (12%)
Current alcohol 179 (72%) 177 (71%)
Obstetric history
Parity (>0) 119 (48%) 122 (49%)
Miscarriage (>0) 3 (1%) 1 (<1%)
Medical disorders
Hypertension 3 (1%) 1 (<1%)
Insulin-dependent diabetes 1 (<1%) 1 (<1%)
Respiratory disease 8 (3%) 17 (7%)
Cardiac disease 2 (1%) 1 (<1%)
Neurological disease 0 1 (<1%)
Skin condition 4 (2%) 8 (3%)
Thrombophilia 2 (1%) 2 (1%)
Current pregnancy
Fetal anomaly scan: twin 1
Normal 242 (97%) 243 (97%)
Deﬁ ned abnormality 3 (1%) 1 (<1%)
Uncertain abnormality 0 0
Not done 5 (2%) 6 (2%)
Fetal anomaly scan: twin 2
Normal 242 (97%) 242 (97%)
Deﬁ ned abnormality 3 (1%) 2 (1%)
Uncertain abnormality 0 0
Not done 5 (2%) 6 (2%)
Amniocentesis for twin 1 abnormal 0 0
Amniocentesis for twin 2 abnormal 0 0
CVS done 1 (<1%) 0
Data are number (%) unless otherwise indicated. CVS=chorionic villus sampling.
Table 1: Baseline characteristics
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analysis, data interpretation, or writing of the report. 
The joint study sponsor in terms of the EU Clinical 
Directive had no role in analysis of data. The 
corresponding author had full access to all the data in 
the study and had ﬁ nal responsibility for the decision to 
submit for publication.
Results 
Figure 1 shows the trial proﬁ le. Participants attended 
clinic visits at the time of randomisation (baseline) and at 
intervals during pregnancy, and were admitted to the 
study hospital for delivery and postnatal care. 
Table 1 shows the baseline demographics and clinical 
characteristics of the participants. Three women in each 
of the progesterone and the placebo groups were lost to 
follow-up (because of withdrawal of consent or not 
traceable after moving out of study area); thus data from 
494 patients were available for the intention-to-treat 
analysis of the primary outcome. No patients were con-
sidered protocol violators, and none were unblinded 
before ascertainment of all outcomes. Thus 494 mothers 
and 988 babies remained for the per-protocol analyses. 
The proportion of women delivering or with an 
intrauterine death before 34 weeks was 61/247 (24·7%) 
in the progesterone group and 48/247 (19·4%) in the 
placebo group (OR 1·36 [95% CI 0·89–2·09], p=0·16; 
table 2). Thus, by contrast with our original hypothesis, 
progesterone did not reduce the incidence of preterm 
delivery or intrauterine death before 34 weeks’ gestation. 
Subgroup analysis of the primary outcome by 
chorionicity suggested an increase in the rate of preterm 
delivery or intrauterine death before 34 weeks in 
association with progesterone in women with 
dichorionic pregnancies (table 2). However, the p value 
for the formal test of interaction between the 
monochorionic and dichorionic groups was not 
signiﬁ cant (p=0·056), implying that the response to 
treatment in the monochorionic and dichorionic groups 
did not diﬀ er signiﬁ cantly. Thus the ﬁ nding of increased 
rates of adverse outcomes in the dichorionic group 
should be interpreted with suitable caution.
Tables 3 and 4 show secondary maternal outcomes, 
table 5 neonatal outcomes, table 6 safety issues, table 7 
side-eﬀ ects, and table 8 maternal satisfaction. The only 
apparent diﬀ erences between the groups were reduced 
odds of caesarean (OR 0·53, 95% CI 0·34–0·84; p=0·006), 
operative vaginal delivery (OR 0·42, 0·21–0·83; p=0·013), 
and nausea (OR 0·43, 0·20–0·94; p=0·035) in the 
progesterone group. The rate of adverse events did not 
diﬀ er between the two groups (table 6).
136 women in the progesterone group and 151 women 
in the placebo group returned diaries indicating that they 
had taken 80% or more of their medication. The 
remainder either did not return their diary or stopped 
early because of preterm delivery, because they were told 
to stop, or because they were incompletely compliant with 
treatment. 
Electronic searching of published work generated 
198 results relevant for meta-analysis. Review of the 
abstracts indicated that only two studies fulﬁ lled the 
inclusion criteria. Relevant data could be abstracted from 
one of these papers.11 In view of the discrepancy between 
the published primary outcome (spontaneous preterm 
delivery before 34 weeks’ gestation) and the outcome we 
planned for the meta-analysis (intrauterine death or any 
preterm delivery before 34 weeks’ gestation) we contacted 
the senior author of the other paper8 who supplied the 
relevant data. A further paper12 was not found on electronic 
searching, but was brought to the attention of the authors 
and considered for inclusion. This paper showed that the 
Progesterone Placebo Odds ratio 
progesterone vs 
placebo or mean 
diﬀ erence (95% CI)†
p value
n Event (%) or 
mean (SD)*
n Event (%) or 
mean (SD)*
Admission to neonatal 
unit
494 167 (33·8%) 494 158 (32·0%) 1·08 (0·76 to 1·54) 0·65
Duration of neonatal unit 
stay: all babies (days)
494 7·5 (19·9) 494 8·7 (23·1) 1·5 (–1·9 to 5·0) 0·38
Duration of neonatal unit 
stay: only babies admitted 
to neonatal unit (days)
167 26·9 (33·5) 158 23·6 (29·5) 3·3 (–5·3 to 11·9) 0·45
These data refer to all twins, both the ﬁ rst and second, with 95% CIs and p values adjusted for clustering among the 
twin set. *Data are event (%) for admission to neonatal unit, and mean (SD) for duration of neonatal unit stay. †Data 
are odds ratio (95% CI) for progesterone versus placebo for admission to neonatal unit, and mean diﬀ erence (95% CI) 
for duration of neonatal unit stay. 
Table 5: Neonatal complications (secondary outcomes)
Progesterone Placebo Mean diﬀ erence 
(95% CI)
p value
n Mean (SD) n Mean (SD)
Gestational age birth (weeks) 247 35·4 (3·5) 247 35·7 (3) –0·3 (–0·9 to 0·3) 0·31
Duration of labour stage 1 (min)* 82 327 (284) 63 360 (380) –33 (–142 to 75) 0·55
Duration of labour stage 2 (min)* 82 102 (94) 63 116 (91) –14 (–45 to 17) 0·36
Duration of labour stage 3 (min)* 82 19 (28) 63 16 (29) 3 (–6 to 12) 0·53
Duration of labour overall (min)* 82 447 (327) 63 496 (418) –48 (–171 to 74) 0·44
*Vaginal deliveries only. 
Table 3: Gestational age at birth and duration of labour (secondary outcomes)
Progesterone Placebo Odds ratio 
progesterone vs 
placebo (95% CI)
p value
n Event (%) n Event (%)
Not recorded 250 14 (5·6%) 250 21 (8·4%) ·· ··
LSCS 250 148 (59·2%) 250 161 (64·4%) 0·53 (0·34–0·84) 0·006
Forceps or ventouse 250 22 (8·8%) 250 30 (12·0%) 0·42 (0·21–0·83) 0·013
SVD or vaginal breech 250 66 (26·4%) 250 38 (15·2%) 1·00 1·00
LSCS=lower-segment caesarean section. SVD=spontaneous vertex delivery.
Table 4: Method of delivery (hierarchical; secondary outcome)
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primary outcome (spontaneous preterm delivery before 
37 completed weeks of gestation) was again diﬀ erent from 
the one that we planned in the meta-analysis, and because 
the paper was published in 1980, we decided that 
contacting the author for further information would not 
be helpful. Both trials included in the meta-analysis were 
rated as of highest quality according to the Jadad score.10 
The pooled OR of the eﬀ ect of progesterone in preterm 
delivery or intrauterine death before 34 weeks’ gestation 
was 1·16 (95% CI 0·89–1·51; ﬁ gure 2). 
Discussion 
We have shown that progesterone did not reduce the 
composite outcome of risk of delivery or intrauterine 
death before 34 weeks of pregnancy in women with twin 
pregnancy. Our results accord with the other large 
published trial11 in twin pregnancy that used 
17-hydroxyprogesterone caproate (250 mg) given 
intramuscularly from 16–20 to 35 weeks, and with the 
most recent meta-analysis on this issue.9 The relative risk 
of preterm birth or intrauterine death before 35 weeks in 
the 655 women available for analysis was 1·1 (95% CI 
0·9–1·3) in the active compared with the placebo group.11
Our study has the following strengths. It was a 
double-blind, placebo-controlled trial with central 
randomisation, and it had a prespeciﬁ ed sample size that 
was achieved, a prespeciﬁ ed primary endpoint and 
analysis plan that was followed, and a high rate of 
follow-up. Loss to follow-up for the primary outcome was 
small. Our exclusion criteria were few, and thus more 
than four-ﬁ fths of women with twin pregnancy were 
eligible for the study. 
Potential limitations of our study are that the uptake of 
the study in eligible participants was less than we initially 
anticipated, with only 40% (500/1249) of eligible women 
agreeing to participate, and that the study was largely 
undertaken in tertiary referral centres. These issues 
could have aﬀ ected the external validity of our trial. The 
overall rate of preterm delivery or intrauterine death 
before 34 weeks was 22% (109/494), which is similar to 
another (singleton) study in which progesterone was 
shown to be eﬀ ective.6 The dose of vaginal progesterone 
was similar to the dose used in that singleton study,6 
although less than that in another.8 The dose we used is 
at the lower end of proven eﬀ ective doses, but 
meta-analyses have not shown a dose-response eﬀ ect.13 
We therefore believe that the dose of progesterone we 
used was unlikely to have been too small.
Our unexpected observation of overall lower rates of 
both caesarean section and operative vaginal delivery in 
the progesterone group should be interpreted with 
caution. We noted no eﬀ ect on any other labour 
parameters and no signiﬁ cant eﬀ ect when we analysed 
pre-labour and post-labour caesarean sections separately. 
The eﬀ ect on caesarean delivery was not detected in other 
large studies using progesterone during twin pregnancy 
(relative risk 1·0, 95% CI 0·9–1·1)11 or singleton 
pregnancy (0·94, 0·68–1·30).7 Progesterone is unlikely to 
have reduced caesarean section by improving fetal 
wellbeing, in view of the trend towards increased 
perinatal mortality that we recorded (14 deaths in the 
progesterone group vs ten in the placebo group). 
Furthermore, progesterone was unlikely to have improved 
uterine contractility during labour since it is known to 
have a relaxant, rather than a stimulatory, eﬀ ect on the 
Progesterone Placebo Odds ratio 
progesterone vs 
placebo (95% CI)
p value
n Event (%) n Event (%)
Bloating 187 6 (3%) 191 5 (3%) 1·23 (0·37–4·11) 0·73
Fluid retention 187 20 (11%) 191 22 (12%) 0·92 (0·48–1·75) 0·80
Breast tenderness 187 14 (7%) 191 12 (6%) 1·20 (0·54–2·68) 0·64
Excessive weight gain 187 2 (1%) 191 2 (1%) 1·02 (0·14–7·33) 0·98
Nausea 187 10 (5%) 191 22 (12%) 0·43 (0·20–0·94) 0·035
Headache 187 8 (4%) 191 17 (9%) 0·45 (0·19–1·09) 0·077
Dizziness 187 8 (4%) 191 9 (5%) 0·90 (0·34–2·40) 0·84
Diﬃ  culty sleeping 187 31 (17%) 191 40 (21%) 0·75 (0·45–1·26) 0·28
Drowsiness 187 8 (4%) 191 4 (2%) 2·09 (0·62–7·06) 0·24
Depression 187 6 (3%) 191 5 (3%) 1·23 (0·37–4·11) 0·73
Itching 187 19 (10%) 191 21 (11%) 0·92 (0·48–1·77) 0·79
Rash 187 7 (4%) 191 4 (2%) 1·82 (0·52–6·32) 0·35
Acne 187 4 (2%) 191 2 (1%) 2·07 (0·37–11·42) 0·41
Excessive hair growth 187 3 (2%) 191 4 (2%) 0·76 (0·17–3·45) 0·73
Hair loss 187 1 (1%) 191 1 (1%) 1·02 (0·06–16·45) 0·99
Jaundice 187 0 191 0 ·· ··
Allergic reactions 187 1 (1%) 191 1 (1%) 1·02 (0·06–16·45) 0·99
Vaginal irritation 187 20 (11%) 191 15 (8%) 1·45 (0·70–2·83) 0·34
Vaginal itching 187 19 (10%) 191 18 (9%) 1·09 (0·55–2·14) 0·81
Vaginal discharge 187 59 (32%) 191 46 (24%) 1·45 (0·92–2·29) 0·11
Vaginal discomfort 187 24 (13%) 191 17 (9%) 1·51 (0·78–2·91) 0·22
Joint pain 173 11 (6%) 176 13 (7%) 0·85 (0·37–1·96) 0·71
Pubic pain 187 6 (3%) 191 5 (3%) 1·23 (0·37–4·11) 0·73
Data shown are any reported symptom at either of the 6-week or the 10-week visits, without adjustment for the 
baseline measure.
Table 7: Maternal symptoms (tertiary outcome)
n (events) in 
progesterone 
group
n (events) in 
placebo 
group
p value*
Mother died 0 0 1·00
Intrauterine death 6 4 0·52
Neonatal death 8 6 0·59
Involved or prolonged inpatient maternal hospital admission 87 (103) 72 (87) 0·16
Involved persistent/signiﬁ cant maternal disability or incapacity 1 0 0·32
Life threatening 1 2 0·56
Chorioamnionitis or intrauterine infection 0 0 1·00
Congenital anomaly or birth defect 0 0 1·00
*p value from exact test. 
Table 6: Safety issues (secondary outcomes)
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uterus.14 Because reduction in caesarean section is one of 
several secondary outcomes in our study, and because of 
the absence of biological plausibility and no conﬁ rmation 
from other studies, we believe that this ﬁ nding is most 
likely to be one of chance. 
The clinical implication of our study is that 
progestogens are not eﬀ ective in women with twin 
pregnancy for prevention of preterm delivery. Although 
six further clinical trials of the eﬀ ect of 17-hydroxy-
progesterone caproate or progesterone in the prevention 
of preterm delivery in twin pregnancy are ongoing—two 
large trials (registration numbers NCT00329914 [with a 
planned sample size of 750] and ISRCTN40512715 [with 
a planned sample size of 660]) and four smaller trials 
(NCT00343265, NCT00480402, NCT00141908, and NCT 
00163020, with a combined planned sample size 
of 957)—unless their combined eﬀ ect size is large with 
an odds ratio of 0·65 or less, they will not change the 
overall conclusion of this and the previous11 study that 
progesterone is ineﬀ ective.
Our results contrast with the randomised trials and 
meta-analyses of high-risk singleton pregnancies in 
which progesterone seems to be eﬀ ective in reducing 
preterm birth, although this reduction will only be 
clinically useful if accompanied by long-term 
improvement in the health of oﬀ spring. At present, 
there is no evidence to suggest that this is the case. This 
issue is being speciﬁ cally addressed in singletons in a 
randomised trial of progesterone, with infant function 
at 2–3 years of age as our primary outcome (OPPTIMUM 
study, registration number ISRCTN14568373). The 
biological mechanism by which preterm delivery occurs 
might be diﬀ erent in twin and singleton pregnancy, and 
this hypothesis merits further study. Perhaps stretching 
of uterine muscle has a substantial role in preterm 
labour in twin pregnancy, and infection and 
inﬂ ammation a role in singletons. We did not recruit 
women with higher multiple pregnancy (eg, triplets), 
but a recent publication did not show any eﬀ ect of 
progesterone in prevention of preterm birth in triplet 
pregnancy.15
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Progesterone Placebo Odds ratio progesterone 
vs placebo (95% CI)
p value
How satisﬁ ed were you with your study treatment overall? (1=very satisﬁ ed; 
10=completely dissatisﬁ ed)
2·8 (2·1) 2·8 (1·9) 0·0 (0·5 to 0·4) 0·89
Do you think your study treatment worked? (1=yes, worked perfectly; 10=no, did not 
work at all)
3·8 (2·3) 3·9 (2·5) –0·1 (0·6 to 0·4) 0·73
How easy was your treatment to use overall? (1=very easy; 10=very diﬃ  cult) 2·6 (1·9) 2·5 (1·7) 0·2 (–0·2 to 0·6) 0·38
How easy was your treatment to insert? (1=very easy; 10=very diﬃ  cult) 2·6 (1·9) 2·4 (1·7) 0·2 (–0·2 to 0·6) 0·30
How easy was your treatment to remember to use? (1=very easy; 10=very diﬃ  cult) 2·6 (1·7) 2·9 (1·7) –0·2 (–0·6 to 0·2) 0·26
How pleasant was your treatment to use? (1=very pleasant; 10=very unpleasant) 4·8 (2·0) 4·9 (1·8) –0·1 (–0·5 to 0·3) 0·60
How messy was your treatment to use? (1=very messy; 10=not at all messy) 5·5 (2·5) 6·1 (2·4) –0·6 (–1·1 to 0·1) 0·026
How uncomfortable was your treatment to use? (1=very uncomfortable; 10=very 
comfortable)
6·4 (2·5) 6·5 (2·3) –0·1 (–0·6  to 0·4) 0·65
Were there many side-eﬀ ects of the study treatment overall? (1=a lot of side-eﬀ ects; 
10=no side-eﬀ ects)
8·2 (2·3) 8·4 (1·9) –0·2 (–0·7 to 0·2) 0·32
An alternative to gel would be an intramuscular injection once per week. If this injection 
were only a bit uncomfortable, which would you prefer? (1=daily vaginal gel; 10=weekly 
injection) 
4·3 (3·6) 4·2 (3·6) 0·2 (–0·6 to 0·9) 0·70
If this injection was quite uncomfortable, which would you prefer? (1=daily vaginal gel; 
10=weekly injection)
3·3 (3·0) 3·1 (2·9) 0·2 (–0·4 to 0·9) 0·50
Overall, how satisﬁ ed were you with participating in the STOPPIT study? (1=very 
satisﬁ ed; 10=completely dissatisﬁ ed)
2·5 (2·2) 2·1 (1·6) 0·4 (–0·1 to 0·8) 0·093
Data are mean (SD) over two visits (at weeks 6 and 10), adjusted for the baseline measure. 
Table 8: Maternal satisfaction (tertiary outcome)
Fonseca8
Rouse11
Norman
Overall
(I2=0·0%, p=0·421)
11
325
247
583
4
93
61
158
13
330
247
590
7
89
48
144
3·95%
61·05%
35·00%
100·00%
0·49 (0·09–2·53)
1·09 (0·77–1·53)
1·36 (0·89–2·09)
1·16 (0·89–1·51)
OR (95% CI)Year
n nEvents Events
Progesterone Placebo Weight (%)
2007
2007
2009
0·0948 1 10·6
Favours progesterone Favours placebo
Figure 2: Meta-analysis of the eﬀ ect of progesterone in prevention of preterm delivery before 34 weeks’ 
duration
The ﬁ gure shows the odds ratio for each study as a square (with size proportional to the amount of information) 
and the horizontal line depicts the 95% CIs. The open diamond indicates the odds ratio (OR) with 95% CI overall. 
The vertical line, at the odds ratio of unity, corresponds to the line of no eﬀ ect.
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